Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes
- 13 August 1998
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 339 (7) , 436-443
- https://doi.org/10.1056/nejm199808133390704
Abstract
Aggregation of platelets is the pathophysiologic basis of the acute coronary syndromes. Eptifibatide, a synthetic cyclic heptapeptide, is a selective high-affinity inhibitor of the platelet glycoprotein IIb/IIIa receptor, which is involved in platelet aggregation. We tested the hypothesis that inhibition of platelet aggregation with eptifibatide would have an incremental benefit beyond that of heparin and aspirin in reducing the frequency of adverse outcomes in patients with acute coronary syndromes who did not have persistent ST-segment elevation.Keywords
This publication has 40 references indexed in Scilit:
- A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable AnginaNew England Journal of Medicine, 1998
- Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial InfarctionNew England Journal of Medicine, 1998
- Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic ComplicationJAMA, 1997
- Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary RevascularizationJournal of the American College of Cardiology, 1997
- Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary interventionThe American Journal of Cardiology, 1995
- Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: Insights from the coronary angioplasty versus excisional atherectomy trial (CAVEAT)Journal of the American College of Cardiology, 1995
- Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary ArteriesJAMA, 1995
- Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgeryThe American Journal of Cardiology, 1994
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trialsPublished by American Medical Association (AMA) ,1991